Browsing tag:


Phase 1 clinical trial results for Ceritinib have revealed affirmative results, leading the FDA to grant an accelerated approval for this impressive drug. Deemed to be “highly active” in the fight against ALK-rearranged non-small-cell lung cancer, Ceritinib is also twenty times more potent than Crizotinib. The exciting results from Novartis’s Phase 1 trial were recently[…]

Read More

On November 21, 2013 the FDA announced the approval of the formidable cancer drug Crizotinib to treat ALK-positive tumors. Patients with metastatic non-small cell lung cancer who have anaplastic lymphoma kinase (ALK)-positive tumors stand to benefit greatly from the Crizotinib FDA approval.  Encouraging data that demonstrated efficacious progression-free survival propelled the Crizotinib FDA approval decision. In 2011[…]

Read More

Crizotinib, CAS number 877399-52-5, is also known as the brand Xalkori. Xalkori, manufactured Pfizer, was approved on August 26, 2011 by the FDA for metastatic non-small cell lung cancer. Crizotinib is ideal for patients who have a certain type of chromosome translocation, specifically one that affects the anaplastic lymphoma kinase, or ALK gene, which causes[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service